Full Show: A New BCMA Test to Track Multiple Myeloma Levels with Dr. James R. Berenson, MD, IMBCR
About admin
View all posts by adminSubscribe
Subscribe to our e-mail newsletter to receive updates.
James R. Berenson, MD
President and CEO - James R. Berenson, MD, Inc.
Medical & Scientific Director - Institute for Myeloma
& Bone Cancer Research (IMBCR)
Chief Executive Officer - Oncotherapeutics
-
Video Updates
- Combined TRAF6 Targeting and Proteasome Blockade has Anti-tumor and Anti-bone Resorptive Effects
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- Outcomes in Multiple Myeloma Patients Evaluated
- Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
-
Video Updates
- The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo
- Oncology CRO Oncotherapeutics Presents at ASH 2011 Annual Meeting
- Understanding Myeloma News About Secondary Cancers and Clotting
-
Dedication of “Determination”
February 22, 2016
Broadcasts